Not sure if this has been posted already or not, but drug company MSD recently acquired a medical drug company EyeBio which develops a drug to treat DME (diabetic macular oedema). 1.3 Bn USD upfront and up to addtional 1.7 Bn USD in milestone payments.
https://www.msd.com/news/msd-to-acquire-eyebio/
This seems the same field (disease) that 2RT is currently authorized in Europe (if I am not mistaken): https://simovision.com/assets/Uploads/Brochure-Ellex-2RT-EN.pdf
Seems like a positive event, which I think signifies how undervalued NovaEye is - not only in the iTrack front, but also in the 2RT side which seems to get no valuation at all.
Not sure if this has been posted already or not, but drug...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.10M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.5¢ | 21.0¢ | $45.70K | 217.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2722 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 57356 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |